Covered recipient · General Payments record
OMOTOLA T'SARUMI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
General Payments · PY2019–2025
$5,285.21
- Reported across 21 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $485.85 | 8 |
| Education | $97.99 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $186.94 | 3 |
| REVANCE THERAPEUTICS, INC. | $182.41 | 2 |
| Teva Pharmaceuticals USA, Inc. | $97.99 | 1 |
| MERZ NORTH AMERICA, INC. | $92.85 | 2 |
| Galderma Laboratories, L.P. | $23.65 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (9)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | $23.65 | 11/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234708974 | CMS |
| Janssen Pharmaceuticals, Inc | $18.24 | 01/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174293460 | CMS |
| Janssen Pharmaceuticals, Inc | $135.12 | 01/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174293431 | CMS |
| Janssen Pharmaceuticals, Inc | $33.58 | 05/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174293425 | CMS |
| MERZ NORTH AMERICA, INC. | $21.16 | 03/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1236971235 | CMS |
| MERZ NORTH AMERICA, INC. | $71.69 | 08/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1236971233 | CMS |
| REVANCE THERAPEUTICS, INC. | $32.41 | 03/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251174121 | CMS |
| REVANCE THERAPEUTICS, INC. | $150.00 | 03/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251174123 | CMS |
| Teva Pharmaceuticals USA, Inc. | $97.99 | 05/22/2025 | Education | Undisputed | 06/30/2026 | 1247432259 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.